Search Results
Your search for ,sIX matches 2810 pages
Showing 401 - 450Sotorasib in Previously Treated Patients With KRAS G12C–Mutated Advanced Pancreatic Cancer
In the phase I/II CodeBreaK 100 trial reported in The New England Journal of Medicine, John H. Strickler, MD, and colleagues found that the KRAS G12C inhibitor sotorasib showed activity in previously treated patients with advanced pancreatic cancer and a KRAS G12C mutation. Study Details In the...
Immune System B Cells May Help to Predict Treatment Response Among Patients With HER2-Positive Breast Cancer
Researchers have found that measuring the activation of immune system B cells may be more effective than measuring the activation of either T cells or tumor-infiltrating lymphocytes (TILs) in predicting whether patients with HER2-positive breast cancer will respond to treatment. These findings were ...
First-Line Atezolizumab Plus Bevacizumab in Metastatic Nonsquamous NSCLC With High Tumor Mutation Burden
In a Spanish phase II trial reported in JAMA Oncology, Mariano Provencio, MD, PhD, and colleagues found that the combination of atezolizumab and bevacizumab was active in the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) with high tumor mutation...
Addition of Adjuvant Nab-paclitaxel to Gemcitabine in Pancreatic Ductal Adenocarcinoma
As reported in the Journal of Clinical Oncology by Margaret A. Tempero, MD, and colleagues, the phase III APACT trial has shown no improvement in independently assessed disease-free survival (the study’s primary endpoint) with the addition of adjuvant nab-paclitaxel to gemcitabine in...
Mitomycin Gel for Upper Tract Urothelial Cancers: Postmarket Analysis
Researchers have performed the first postmarkert analysis of a novel delivery system of mitomycin—a gel formation, also known as UGN-101—to treat upper tract urothelial cancers, according to a novel study published by Woldu et al in Urologic Oncology. Their findings showcase how the treatment is...
Crizotinib Combined With Chemotherapy in Pediatric ALK-Positive Anaplastic Large Cell Lymphoma
As reported in the Journal of Clinical Oncology by Lowe et al, findings in an arm of the Children’s Oncology Group phase II ANHL12P1 trial (arm CZ) showed high event-free and overall survival rates with the addition of crizotinib to chemotherapy in newly diagnosed pediatric patients with...
Study Finds Lifileucel Active in Advanced Melanoma After Disease Progression on Immune Checkpoint Inhibitors
Cell therapy with tumor-infiltrating lymphocytes (TIL) may address an important unmet need for patients with difficult-to-treat melanoma after disease progression on immune checkpoint inhibitors, according to data presented during the 2022 Society for Immunotherapy of Cancer (SITC) Annual ...
Cardiovascular Events Before and After Initiation of Immune Checkpoint Inhibitor Therapy for Cancer: Agreement Between ICD-Coded and -Adjudicated Events
In a study reported in JACC: CardioOncology, Kondapalli et al found that cardiovascular events common in the general population were observed both prior to and after initiation of immune checkpoint inhibitor therapy for cancer; myocarditis was more common posttreatment, but infrequent. Agreement...
Sodium Thiosulfate to Reduce the Risk of Cisplatin-Related Ototoxicity in Pediatric Patients With Localized Solid Tumors
On September 20, 2022, sodium thiosulfate was approved to reduce the risk of ototoxicity associated with cisplatin in pediatric patients (aged ≥ 1 month) with localized, nonmetastatic solid tumors.1 Supporting Efficacy Data Approval was based on findings in the multicenter open-label SIOPEL 6...
Tremelimumab Combined With Durvalumab and Platinum-Based Chemotherapy in Metastatic NSCLC
On November 10, 2022, tremelimu-mab in combination with durvalumab and platinum-based chemotherapy was approved for patients with metastatic non–small cell lung cancer (NSCLC) with no sensitizing EGFR mutation or ALK genomic tumor aberrations.1 Supporting Efficacy Data Approval was supported by...
First-Line Nivolumab/Ipilimumab vs EXTREME Regimen in Recurrent or Metastatic Head and Neck Cancer
The final results of the phase III CheckMate 651 trial showed no significant overall survival benefit with first-line nivolumab/ipilimumab vs the EXTREME regimen (cetuximab plus cisplatin or carboplatin plus fluorouracil for up to six cycles, followed by cetuximab maintenance) in recurrent or...
Study Reports Activity With Oncolytic Vaccine Plus Pembrolizumab in BCG-Unresponsive Bladder Cancer
An oncolytic therapy delivered within the urinary bladder in combination with pembrolizumab has yielded the “best results seen in the field” in patients with bacillus Calmette-Guérin (BCG)-unresponsive bladder cancer, according to data presented during the 2022 Society for Immunotherapy of Cancer...
Adavosertib in Refractory Solid Tumors With CCNE1 Amplification
In a phase II trial reported in the Journal of Clinical Oncology, Fu et al found that the WEE1 kinase inhibitor adavosertib was active in patients with refractory solid tumors with CCNE1 amplification, with evidence of increased activity in epithelial ovarian cancer. Study Details In the trial, 30...
Zanubrutinib Found Superior to Ibrutinib for CLL and SLL
Zanubrutinib showed superior efficacy to ibrutinib—with fewer side effects—in the first head-to-head comparison between the Bruton’s tyrosine kinase (BTK) inhibitors among patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), according to data presented by Jennifer...
Simplified Treatment Regimen Reduces Early Deaths in Patients With APL
The use of a simplified treatment regimen by oncologists—along with management recommendations and 24/7 support provided by a limited and dedicated group of academic disease experts—resulted in a decrease in early deaths from acute promyelocytic leukemia (APL). In the multicenter prospective trial...
Breast-Conserving Therapy May Be a Treatment Option for Some Patients With Multiple Ipsilateral Breast Lesions
Patients with multiple tumors in a single breast who underwent a lumpectomy followed by radiation therapy had local recurrence rates comparable to those historically observed in patients with a single tumor, according to new findings presented by Judy C. Boughey, MD, and colleagues at the 2022 San...
Experimental Drug Under Study in Liver Cancer
A new drug that inhibits an enzyme playing a crucial role in cell division and growth has shown signs of anticancer activity with manageable side effects in patients with liver cancer who have been treated unsuccessfully previously with up to three lines of treatment. These findings were presented...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Bolivia
The ASCO Post is pleased to continue this occasional special focus on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Bolivia. The aim of this special feature is to highlight the global cancer burden for various countries of the...
Patient-Reported Outcomes Study Finds Severe Symptoms in Meaningful Minority of Patients With Cancer
Routine monitoring in the real world may help to identify patients with cancer who are experiencing challenging symptoms, without significantly disrupting clinical workload, according to data presented during the 2022 ASCO Quality Care Symposium.1,2 The analysis of nearly 40,000 patient-reported...
Addition of First-Line Atezolizumab to Vemurafenib/Cobimetinib in BRAF V600–Mutant Advanced Melanoma
As reported in The Lancet Oncology by Paolo A. Ascierto, MD, and colleagues, the second interim overall survival analysis of the phase III IMspire150 trial has shown a numeric but statistically nonsignificant improvement with the addition of first-line atezolizumab to vemurafenib and cobimetinib in ...
Neoadjuvant T-DXd Shows Clinical Activity in Patients With HER2-Low Breast Cancer
Patients with localized, hormone receptor (HR)-positive, HER2-low breast cancer treated with fam-trastuzumab deruxtecan-nxki (T-DXd) in the neoadjuvant setting had an overall response rate of 75% without combining the agent with anastrozole and 63% in combination with anastrozole, according to...
DNA Repair Protein MRE11 Expression and Disease-Specific Mortality Among Patients With Muscle-Invasive Bladder Cancer Receiving Trimodality Therapy
In a retrospective analysis reported in JAMA Network Open, Magliocco et al found that among patients with muscle-invasive bladder cancer receiving bladder-preserving trimodality therapy, those with a lower expression of the DNA repair protein MRE11 had significantly poorer disease-specific...
Does CBD Oil Improve Symptom Distress in Patients With Advanced Cancer Receiving Palliative Care?
In an Australian phase IIb trial (MedCan1-CBD) reported in the Journal of Clinical Oncology, Hardy et al found that use of cannabidiol (CBD) oil did not improve symptom distress vs placebo in adult patients with advanced cancer receiving palliative care. Study Details The double-blind multicenter...
Novel Bispecific Antibody Zanidatamab in Advanced HER2-Expressing or HER2-Amplified Cancers
In a phase I dose-escalation and expansion study reported in The Lancet Oncology, Funda Meric-Bernstam, MD, and colleagues found that zanidatamab, a novel bispecific monoclonal antibody directed against two nonoverlapping domains of HER2, showed activity in locally advanced or metastatic...
Importance of Screening Programs in Diagnosing Cancer in Patients With Type 2 Diabetes
Researchers have discovered that patients with type 2 diabetes who develop cancer are more likely to be diagnosed with advanced disease if they do not undergo routine screenings, according to a new study published by Jansana et al in the European Journal of Cancer. The new findings were also...
Researchers Find Changes in Blood Proteins up to 2 Years Before Breast Cancer Diagnosis
Researchers have found changes in the levels of particular proteins in patients’ blood up to 2 years before they were diagnosed with breast cancer, according to a novel study published by Hagenaars et al in the European Journal of Cancer. The study, also presented at the 13th European Breast Cancer ...
Comparison of Bevacizumab Durations in Front-Line Therapy for Advanced Ovarian Cancer
In a European phase III trial (AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15) reported in the Journal of Clinical Oncology, Jacobus Pfisterer, MD, PhD, and colleagues found no significant progression-free survival benefit with the extension of bevacizumab treatment from 15 to 30 months in patients...
POSEIDON Trial: First-Line Durvalumab With or Without Tremelimumab Plus Chemotherapy in Metastatic NSCLC
As reported in the Journal of Clinical Oncology by Melissa L. Johnson, MD, and colleagues, the pivotal phase III POSEIDON trial has shown significantly improved progression-free and overall survival with the addition of tremelimumab and durvalumab to platinum-based chemotherapy in the first-line...
Sodium Thiosulfate to Reduce the Risk of Cisplatin-Related Ototoxicity in Pediatric Patients With Localized Solid Tumors
On September 20, 2022, sodium thiosulfate was approved to reduce the risk of ototoxicity associated with cisplatin in pediatric patients (aged ≥ 1 month) with localized, nonmetastatic solid tumors.1 Supporting Efficacy Data Approval was based on findings in the multicenter open-label SIOPEL 6...
Selpercatinib Approved for Advanced RET Fusion–Positive Solid Tumors and Advanced RET Fusion–Positive NSCLC
On September 21, 2022, selpercatinib was granted accelerated approval for adults with locally advanced or metastatic solid tumors with RET gene fusion whose disease has progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.1 On the same day,...
First-Line Pembrolizumab vs Chemotherapy in Advanced PD-L1–Positive NSCLC Without EGFR/ALK Alterations
As reported in the Journal of Clinical Oncology by Gilberto de Castro, Jr, MD, PhD, and colleagues, 5-year follow-up of the KEYNOTE-042 trial showed a maintained overall survival benefit with first-line pembrolizumab vs chemotherapy in patients with non–small cell lung cancer (NSCLC) with a PD-L1...
Comparison of Two Chemotherapy Regimens for Newly Diagnosed Ewing Sarcoma
As reported in The Lancet by Brennan et al, the European phase III EURO EWING 2012 trial found improved event-free survival with a standard U.S. chemotherapy regimen vs a standard European regimen in newly diagnosed patients with Ewing sarcoma. As stated by the investigators, “Internationally, a...
FDA Approves Tremelimumab in Combination With Durvalumab and Platinum-Based Chemotherapy for Metastatic NSCLC
On November 10, the U.S. Food and Drug Administration (FDA) approved tremelimumab (Imjudo) in combination with durvalumab (Imfinzi) and platinum-based chemotherapy for adult patients with metastatic non–small cell lung cancer (NSCLC) with no EGFR mutations or ALK genomic tumor aberrations. ...
KEYNOTE-412: Pembrolizumab Plus Chemoradiation Falls Short in Locally Advanced Head and Neck Cancer
Pembrolizumab plus chemoradiation failed to demonstrate a statistically significant improvement in event-free survival vs chemoradiation alone in patients with locally advanced head and neck squamous cell carcinoma, but favorable numerical trends were demonstrated, according to results of the phase ...
POSEIDON Follow-up Suggests Chemoimmunotherapy Triplet Extends Survival in Difficult-to-Treat NSCLC Mutational Subtypes
After 4 years, a limited course of five cycles of tremelimumab added to durvalumab plus chemotherapy extended overall survival in patients with metastatic non–small cell lung cancer (NSCLC) compared with chemotherapy alone, according to an updated exploratory analysis of the phase III POSEIDON...
ECHELON-1 Shows Benefit for First-Line Brentuximab Vedotin Plus AVD in Advanced Hodgkin Lymphoma
The results of ECHELON-1 were presented by David J. Straus, MD, of Memorial Sloan Kettering Cancer Center, New York, at the 2022 National Comprehensive Cancer Network (NCCN) Annual Congress: Hematologic Malignancies. Dr. Straus said: “It is a great honor and privilege to present updated results...
Lutetium Lu-177 Vipivotide Tetraxetan for PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
On March 23, 2022, the radioligand therapeutic agent lutetium Lu-177 vipivotide tetraxetan was approved for treatment of patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer who have been treated with an androgen receptor pathway inhibitor ...
Newly Diagnosed AML: Induction to Maintenance
When it is dark enough, you can see the stars.” —Ralph Waldo Emerson Low-intensity therapy for older or unfit patients with acute myeloid leukemia (AML) was introduced in the early 2000s in the form of low-dose cytarabine or hypomethylation therapy (azacitidine or decitabine). Recent studies...
Effect of Smartphone Psychotherapy Apps on Fear of Recurrence Among Young Breast Cancer Survivors
In a Japanese trial (J-SUPPORT 1703) reported in the Journal of Clinical Oncology, Akechi et al found that 8-week use of smartphone psychotherapy apps was associated with significant benefits in reducing the fear of recurrence in breast cancer survivors aged 20 to 49 years. Study Details In the...
Phase I Trial Shows Experimental Mini-Protein May Be Able to Inhibit the Cancer-Driving MYC Gene
Researchers have found that a new drug may be able to target—and for the first time, inhibit—the function of the MYC gene. Until now, no other drug has been able to do this safely and effectively, according to findings from a phase I clinical trial published by Garralda et al in the European...
Small Study of Experimental Drug to Treat Liver Cancer Shows Evidence of Activity With Manageable Side Effects
A new drug designed to inhibit an enzyme that plays a crucial role in cell division and growth has shown signs of anticancer activity with manageable side effects in patients with liver cancer and up to three lines of previous unsuccessful treatment, according to a new study published by Reig et al ...
Concurrent Olaparib and Radiotherapy for Triple-Negative Breast Cancer
In a French phase I trial reported in JAMA Oncology, Loap et al found that concurrent olaparib and radiotherapy was well tolerated in patients with triple-negative breast cancer who had incomplete pathologic response or unresectable disease after neoadjuvant chemotherapy. Survival outcomes with the ...
Researchers Identify Specific Mutations in the BRAF Gene That May Affect Response to Treatment and Survival in Adult Brain Cancers
Researchers have identified a range of genetic mutations in gliomas that may help them understand how different mutations in the BRAF gene interact with other gene mutations—and which ones are more susceptible to targeted treatments in adults—according to a new study published by Schreck et al in...
Pembrolizumab Plus Chemoradiation Therapy Falls Short in Locally Advanced Head and Neck Cancer
Pembrolizumab plus chemoradiation therapy failed to demonstrate a statistically significant improvement in event-free survival vs chemoradiation therapy alone in patients with locally advanced head and neck squamous cell carcinoma, but favorable numerical trends were demonstrated, according to...
NICHE-2: ‘Unprecedented’ Waterfall Plot Achieved With Neoadjuvant Immunotherapy in dMMR Colon Cancer
Treatment with neoadjuvant immunotherapy in colon cancer resulted in major pathologic responses in 95% of patients, NICHE-2 investigators reported at the European Society for Medical Oncology (ESMO) Congress 2022.1 Additionally, after 4 weeks of nivolumab plus ipilimumab, 67% of patients with...
POSEIDON Follow-up Suggests Chemoimmunotherapy Triplet Extends Survival in Difficult-to-Treat NSCLC Mutational Subtypes
After 4 years, a limited course of five cycles of tremelimumab added to durvalumab plus chemotherapy extended overall survival in patients with metastatic non–small cell lung cancer (NSCLC) compared with chemotherapy alone, according to an updated exploratory analysis of the phase III POSEIDON...
First-Line Toripalimab Plus Chemotherapy in Advanced NSCLC: CHOICE-01
As reported in the Journal of Clinical Oncology by Wang et al, a Chinese phase III trial (CHOICE-01) has shown prolonged progression-free survival with the addition of the anti–PD-1 monoclonal antibody toripalimab to platinum-based chemotherapy in the first-line treatment of patients with advanced...
EXTEND Trial: Metastasis-Directed Radiation Therapy Plus Hormone Therapy May Improve Progression-Free Survival in Patients With Advanced Prostate Cancer
Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to intermittent hormone therapy improved progression-free survival in patients with oligometastatic prostate cancer. Findings from the multicenter EXTEND trial were...
Elacestrant Improves Progression-Free Survival vs Standard Endocrine Therapy in Previously Treated Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer
As reported in the Journal of Clinical Oncology by François-Clément Bidard, MD, PhD, of the Institut Curie, Paris and Saint Cloud, and colleagues, the phase III EMERALD trial has shown prolonged progression-free survival with the oral selective estrogen receptor degrader elacestrant vs standard...
Effect of Goals-of-Care Program for Inpatients at a Comprehensive Cancer Center During the COVID-19 Pandemic
As reported in the Journal of Clinical Oncology by David Hui, MD, MSc, and colleagues, an interdisciplinary goals-of-care program instituted at The University of Texas MD Anderson Cancer Center in response to anticipated COVID-19–related increases in need for intensive care unit (ICU) use resulted ...
